Effect of overexpression of wild‐type or mutant parkin on the cellular response induced by toxic insults
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Mutations in parkin are involved in some cases of autosomal recessive juvenile parkinsonism (AR‐JP), but it is not known how they result in nigral cell death. We examined the effect of parkin overexpression on the response of cells to various insults. Wild‐type and AR‐JP‐associated mutant parkins (Del3‐5, T240R, and Q311X) were overexpressed in NT‐2 and SK‐N‐MC cells. Overexpressed wild‐type parkin delayed cell death induced by serum withdrawal, H 2 O 2, 1‐methyl‐4‐phenylpyridinium (MPP+), or 4‐hydroxy‐2‐trans‐nonenal (HNE) but did not delay cell death caused by the proteasome inhibitor lactacystin. Increases in damage to proteins (protein carbonyls and 3‐nitrotyrosine) were attenuated by wild‐type parkin after serum withdrawal or exposure to H 2 O 2, MPP+, or HNE but not after exposure to lactacystin. The mutant parkins (of all types) markedly accelerated cell death in response to all the insults, accompanied by increased levels of 8‐hydroxyguanine, protein carbonyls, lipid peroxidation, and 3‐nitrotyrosine and decreased levels of GSH. The viability loss induced by all the insults showed apoptotic features. The presence of parkin mutations in substantia nigra in Parkinson's disease may increase neuronal vulnerability to a range of toxic insults. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Self-citationFamilial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 4×
“Parkin has been identified as an ubiquitin-protein ligase containing 465 amino acids (Shimura et al., 2000).”
BackgroundInfluentialHalliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Self-citationMitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice
Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845 · cited 2×
“(Sian et al., 1994; Yoritaka et al., 1996; Alam et al., 1997a,b; Beal, 1997; Jenner and Olanow, 1998).”
BackgroundSelf-citationProteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653 · cited 2×
“…1997); the mitochondrial complex I inhibitor MPPþ (Singer et al., 1987), because complex I activity is decreased in PD (Schapira, 1994); and an inhibitor of proteasomal function, lactacystin (Fenteany and Schreiber, 1998), because proteasomal function is impaired in PD (McNaught and Jenner, 2001).”
BackgroundSelf-citationLyras, L., Cairns, N. J., Jenner, A., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052061.x · Cited by 531 · cited 1×
“DNA extraction and assessment of purity were carried out as described by Lyras et al. (1997).”
MethodSelf-citationWhat nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo?
Halliwell, B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00469-9 · Cited by 472 · cited 2×
“By ELISA, levels of 3-NT, a biomarker of attack of RNS on proteins (Halliwell, 1997), were significantly higher in mutant parkin transfectants but were lower in cells expressing WT parkin (P < 0.”
BackgroundInfluentialSelf-citationPoint Mutations (Thr240Arg and Ala311Stop) in theParkinGene
Hattori, N., Matsumine, H., Asakawa, S., Kitada, T., Yoshino, H., Elibol, B., Brookes, A. J., Yamamura, Y., Kobayashi, T., Wang, M., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9134 · Cited by 181
Hyun, D.-H., Lee, M., Hattori, N., Kubo, S.-I., Mizuno, Y., Halliwell, B., & Jenner, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200666200 · Cited by 172
Self-citation
Cited by
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S. R., & Chesselet, M.-F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 913
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
“Parkin expression is upregulated after exposure to the complex I inhibitor MPP + in neuronal cell”
BackgroundParkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
Self-citationMitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
Metadata
- Authors
- Hyun, D., Lee, M., Halliwell, B., & Jenner, P.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2005-08-29
- Volume
- 82
- Issue
- 2
- Pages
- 232-244
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W1977233896
- Cited by
- 46
- References
- 11
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.